HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

Abstract
The primary objective of this 2-part phase 1/2 study was to determine the maximum-tolerated dose (MTD) of the potent and selective Aurora B kinase inhibitor barasertib (AZD1152) in patients with newly diagnosed or relapsed acute myeloid leukemia (AML). Part A determined the MTD of barasertib administered as a continuous 7-day infusion every 21 days. In part B, the efficacy of barasertib was evaluated at the MTD. In part A, 32 patients were treated with barasertib 50 mg (n = 3), 100 mg (n = 3), 200 mg (n = 3), 400 mg (n = 4), 800 mg (n = 7), 1200 mg (n = 6), and 1600 mg (n = 6). Dose-limiting toxicities (stomatitis/mucosal inflammation events) were reported in the 800 mg (n = 1), 1200 mg (n = 1), and 1600 mg (n = 2) groups. The MTD was defined as 1200 mg. In part B, 32 patients received barasertib 1200 mg. In each part of the study, 8 of 32 patients had a hematologic response according to Cheson AML criteria. The most commonly reported grade ≥ 3 events were febrile neutropenia (n = 24) and stomatitis/mucosal inflammation (n = 16). We concluded that the MTD of barasertib is 1200 mg in patients with relapsed or newly diagnosed AML. Toxicity was manageable and barasertib treatment resulted in an overall hematologic response rate of 25%. This study is registered at www.ClinicalTrials.gov as NCT00497991.
AuthorsBob Löwenberg, Petra Muus, Gert Ossenkoppele, Philippe Rousselot, Jean-Yves Cahn, Norbert Ifrah, Giovanni Martinelli, Sergio Amadori, Ellin Berman, Pieter Sonneveld, Mojca Jongen-Lavrencic, Sophie Rigaudeau, Paul Stockman, Alison Goudie, Stefan Faderl, Elias Jabbour, Hagop Kantarjian
JournalBlood (Blood) Vol. 118 Issue 23 Pg. 6030-6 (Dec 01 2011) ISSN: 1528-0020 [Electronic] United States
PMID21976672 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study)
Chemical References
  • 2-((3-((4-((5-(2-((3-fluorophenyl)amino)-2-oxoethyl)-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)(ethyl)amino)ethyl dihydrogen phosphate
  • Organophosphates
  • Protein Kinase Inhibitors
  • Quinazolines
  • AURKB protein, human
  • Aurora Kinase B
  • Aurora Kinases
  • Protein Serine-Threonine Kinases
Topics
  • Aged
  • Aged, 80 and over
  • Aurora Kinase B
  • Aurora Kinases
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Leukemia, Myeloid, Acute (drug therapy)
  • Male
  • Middle Aged
  • Organophosphates (administration & dosage, adverse effects, pharmacokinetics)
  • Protein Kinase Inhibitors (adverse effects, pharmacokinetics)
  • Protein Serine-Threonine Kinases (antagonists & inhibitors)
  • Quinazolines (administration & dosage, adverse effects, pharmacokinetics)
  • Recurrence
  • Severity of Illness Index

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: